Castle Biosciences Stock Price, News & Analysis

Castle Biosciences presented new data at the 2024 ASDS Annual Meeting supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding skin cancer treatment decisions. The CONNECTION study showed that using DecisionDx-Melanoma could reduce unnecessary sentinel lymph node biopsies (SLNB) by up to 64% in patients with T1 melanoma tumors, while maintaining high survival rates. For squamous cell carcinoma (SCC), DecisionDx-SCC demonstrated utility in guiding radiologic surveillance imaging decisions for patients with stage T2b tumors. The test identified low-risk patients who could safely defer imaging and higher-risk patients who may benefit from imaging for early detection of disease progression.

Castle Biosciences announced two recent studies supporting the clinical need for its MyPath® Melanoma gene expression profile (GEP) test. The studies, published in the Journal of Cutaneous Pathology and Melanoma Management, demonstrate:

• Significant disagreement in diagnosing melanocytic lesions using pathology alone
• Variability in surgical management among dermatologists
• Risk-aligned changes and increased confidence in decisions resulting from GEP testing

Key findings include:

• 24% of suspicious lesions had differing diagnoses by nine board-certified dermatopathologists
• 84.2% of clinicians decreased recommended surgical margins with benign GEP results
• 100% of clinicians increased surgical excision recommendations with malignant GEP results
• Overall increase in patient management plan confidence with GEP results

Castle Biosciences (Nasdaq: CSTL), a company focused on improving health through innovative diagnostic tests, has announced the release date for its third quarter 2024 financial results. The company will disclose its financial performance for the quarter and nine months ended Sept. 30, 2024, after market close on Monday, Nov. 4, 2024.

Following the release, Castle Biosciences will host a conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the results. Interested parties can access the live webcast through the provided link or via the Investor Relations page on the company's website. For those joining by phone, dial-in details for both U.S. and international participants are provided, along with the access code. A brief Q&A session will follow management's commentary.

Castle Biosciences (Nasdaq: CSTL) has announced its sponsorship of the 71st Annual Montagna Symposium on the Biology of the Skin, scheduled for Oct. 17-21, 2024, in Stevenson, Washington. The event, hosted by the Oregon Health & Science University Department of Dermatology, aims to bring together clinicians and scientists to explore focused aspects of dermatology and skin biology.

Dr. Matthew Goldberg, SVP of medical at Castle Biosciences, expressed pride in supporting the symposium's mission to exchange knowledge and integrate recent discoveries into clinical practice. The Montagna Symposium, established in 1950, has attracted over 5,000 attendees and serves as a platform for new concepts in cutaneous biology.

This year's symposium will focus on skin of color dermatology, covering topics such as genetics, social determinants of health, and cutaneous disorders affecting people with pigmented skin. Dr. Tamia Harris-Tryon, the symposium program chair, highlighted the importance of support from organizations like Castle Biosciences in challenging disease management paradigms for improved patient care.

Castle Biosciences announced new data presentations for its DecisionDx-Melanoma and DecisionDx-UM tests at the 21st International Congress of the Society for Melanoma Research (SMR). A prospective, multicenter study of 876 patients with Stage I-III cutaneous melanoma showed that DecisionDx-Melanoma significantly stratified patients by recurrence risk and added prognostic value to AJCC staging. Patients with Class 1A results had higher three-year recurrence-free survival compared to Class 1B/2A or 2B (p<0.001).

The company will also present data on DecisionDx-UM for uveal melanoma, confirming PRAME status as a risk modifier. Castle Biosciences' CEO Derek Maetzold stated that their tests provide clinical value beyond current staging methods, enabling improved risk-aligned treatment decisions associated with better outcomes.

Castle Biosciences (Nasdaq: CSTL) announced a groundbreaking ceremony for its new corporate headquarters in Friendswood, Texas. The event, scheduled for Oct. 22, 2024, marks the start of construction on a four-story, 80,000 square foot Class A office building. The 23-acre campus will feature amenities like a covered rooftop deck, corporate fitness center, walking trails, and covered pavilions.

Derek Maetzold, CEO of Castle Biosciences, emphasized the company's commitment to its employees and the community. The new facility is designed to foster collaboration and support future growth. Jason Tramonte Jr., the project's architect, highlighted the employee-centric focus in the design. Castle Biosciences, founded in 2008, also operates clinical laboratories in Phoenix and Pittsburgh.

Castle Biosciences (Nasdaq: CSTL) announced new data demonstrating the effectiveness of its DecisionDx-SCC test in risk stratification for high-risk cutaneous squamous cell carcinoma (SCC) patients, particularly those with suppressed immune systems. The data, to be presented at the ASTRO 2024 Annual Meeting, shows that the test can guide treatment intensification decisions, such as adjuvant radiation therapy.

The study analyzed 954 SCC patients with at least one NCCN high-risk factor. For patients with BWH T1 tumors, the DecisionDx-SCC test further stratified risk regardless of immune status. For immune suppressed patients with T2a tumors, the test identified those with more favorable (Class 1) and less favorable (Class 2A/2B) survival rates. The results suggest that treatment intensification should be considered for immune suppressed patients with BWH T2a SCC tumors, guided by DecisionDx-SCC test results.

Castle Biosciences will present new data on its TissueCypher Barrett's Esophagus test at the American Foregut Society 2024 Annual Meeting. The data demonstrates the test's ability to independently predict the risk of esophageal cancer progression in patients with Barrett's esophagus (BE).

Key findings include:

• TissueCypher alone is the strongest predictor of progression to esophageal cancer, outperforming combinations with clinicopathologic risk factors.
• For non-dysplastic BE patients, TissueCypher was the only significant predictor of progression.
• The test guided risk-aligned management decisions in 86% of patients, leading to upstaged management in 21% and supporting long-interval surveillance in 90% of low-risk patients.

These results highlight TissueCypher's clinical value in identifying high-risk patients and tailoring treatment plans based on cancer progression likelihood.

Castle Biosciences (Nasdaq: CSTL) announced that its Chief Operating Officer, Kristen Oelschlager, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by the Arizona Bioindustry Association (AZBio). Oelschlager, a registered nurse with over 15 years of experience in clinical nursing, operations services, and research, is recognized for her significant contributions to the progression of the bioscience industry in Arizona.

As a co-founder of Castle Biosciences in 2008, Oelschlager has played a important role in the company's growth and success. Castle Biosciences specializes in innovative testing solutions to guide treatment decisions for cancer patients. The award will be presented at the AZBio Awards on September 18, 2024, at the Phoenix Convention Center.